Tiwari Manju
Department of Biochemistry and Genetics, Barkatullah University, Bhopal, Madhya Pradesh, India.
Asian J Pharm Sci. 2017 May;12(3):209-215. doi: 10.1016/j.ajps.2017.01.003. Epub 2017 Feb 1.
Inflammation remains a key event during most of the diseases and physiological imbalance. Acute inflammation is an essential physiological event by immune system for a protective measure to remove cause of inflammation and failure of resolution lead to chronic inflammation. Over a period of time, a number of drugs mostly chemical have been deployed to combat acute and chronic inflammation. Recently, enzyme based anti-inflammatory drugs became popular over conventional chemical based drugs. Serratiopeptidase, a proteolytic enzyme from trypsin family, possesses tremendous scope in combating inflammation. Serine protease possesses a higher affinity for cyclooxygenase (COX-I and COX-II), a key enzyme associated with production of different inflammatory mediators including interleukins (IL), prostaglandins (PGs) and thromboxane (TXs) etc. Currently, arthritis, sinusitis, bronchitis, fibrocystic breast disease, and carpal tunnel syndrome, etc. are the leading inflammatory disorders that affected the entire the globe. In order to conquer inflammation, both acute and chronic world, physician mostly relies on conventional drugs. The most common drugs to combat acute inflammation are Nonsteroidal anti-inflammatory drugs (NSAIDs) alone and or in combination with other drugs. However, during chronic inflammation, NSAIDs are often used with steroidal drugs such as autoimmune disorders. These drugs possess several limitations such as side effects, ADR, etc. In order to overcome these limitations and complications, enzyme based drugs (anti-inflammatory) emerged, and aim for a new high since the last decade. Serine protease, the largest proteolytic family has been reported for several therapeutic applications, including anti-inflammatory. Serratiopeptidase is a leading enzyme which has a very long history in medical as an effective anti-inflammatory drug. Current study emphasizes present scenario and future prospect of serratiopeptidase as an anti-inflammatory drug. The study also illustrates a comparative analysis of conventional drugs and enzyme based therapeutic to combat inflammation.
炎症仍然是大多数疾病和生理失衡过程中的关键事件。急性炎症是免疫系统的一种重要生理事件，是一种保护性措施，用于消除炎症原因，而炎症消退失败会导致慢性炎症。在一段时间内，人们使用了许多主要为化学药物来对抗急性和慢性炎症。最近，基于酶的抗炎药物比传统的化学药物更受欢迎。沙雷肽酶是一种来自胰蛋白酶家族的蛋白水解酶，在对抗炎症方面具有巨大潜力。丝氨酸蛋白酶对环氧化酶（COX-I和COX-II）具有更高的亲和力，环氧化酶是一种与包括白细胞介素（IL）、前列腺素（PGs）和血栓素（TXs）等不同炎症介质产生相关的关键酶。目前，关节炎、鼻窦炎、支气管炎、纤维囊性乳腺病和腕管综合征等是影响全球的主要炎症性疾病。为了战胜急性和慢性炎症，医生大多依赖传统药物。对抗急性炎症最常用的药物是单独使用非甾体抗炎药（NSAIDs）或与其他药物联合使用。然而，在慢性炎症期间，NSAIDs通常与甾体药物如自身免疫性疾病一起使用。这些药物存在一些局限性，如副作用、药物不良反应等。为了克服这些局限性和并发症，基于酶的药物（抗炎药）应运而生，并自上世纪九十年代以来一直瞄准新的高度。丝氨酸蛋白酶是最大的蛋白水解酶家族，已被报道有多种治疗应用，包括抗炎作用。沙雷肽酶是一种领先的酶，作为一种有效的抗炎药物在医学上有着悠久的历史。当前的研究强调了沙雷肽酶作为抗炎药物的现状和未来前景。该研究还对传统药物和基于酶的抗炎治疗进行了比较分析。
